drugset / Trial / NCT04743141
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Timeline
- Start
- 2021-04-28
- Primary completion
- 2030-07-31
- Completion
- 2030-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rimegepant | Small molecule | 35 mg | — |
| Subject | Rimegepant | Small molecule | 50 mg | — |
| Subject | Rimegepant | Small molecule | 75 mg | — |
Indications
No indication recorded.